Latest database descriptions

Evaluate on a prospective basis the predictive value of ANS activity, and its decline during the follow-up, on the occurrence of serious cerebral events, and on mortality all cause considered, in a general population of homogeneous age, 65 at inclusion.

Secondary objectives have been defined, analyzing the association between ANS and:
1) The presence and severity of cerebrovascular accidents at NRM imaging;
2) Neuropsychological performances;
3) Classic cardiovascular risk factors;
4) Genetic of the specific receptors of the neurotransmitters directly implied;
5) Sleep respiratory pathologies;
6) Realization of temporal analysis to determine chronological sequences of the decline of ANS activity and pathological conditions occurrence, including emerging conditions, such as sleep respiratory pathologies.

In this study we will examine patients who have undergone anterior cruciate and/or posterior cruciate ligament and/or multi ligaments reconstruction to determine the rate of re-injury, contralateral tear and functional outcomes at least two years after surgery.

To describe the treatment patterns of advanced (unresectable locally advanced or metastatic) STS (including viscus sarcoma) patients in France.

Secondary objectives:
- To describe STS (including viscus sarcoma) patients characteristics (sociodemographic data, type of sarcoma, histological subtype, tumor location, stage of the disease etc).
- To assess the STS (including viscus sarcoma) incidence in France
- To describe STS diagnosis (anatomopathology double review) and treatment history
- To describe the duration of the different treatments of STS disease

To assess the RAS (KRAS and NRAS exons 2,3 and 4) mutation screening test request and realisation rates in patients with a recent diagnosis of metastatic colorectal cancer.

Secondary objectives:
- To describe changes in the KRAS (exon 2) mutation test request rate between 2011 and 2014;
- To describe the reasons for requesting/not requesting and performing/not performing these tests as a function of physician and patient profiles
- To describe and to analyse the impact of KRAS (exons 2,3 and 4) and NRAS (exons 2.3 and 4) results, the anatomopathology department availability to provide the tests, and the BRAF result, on therapeutic decision-making or changes in ongoing treatment;
- To describe and analyse clinical characteristics of patients and treatments planned and received as first-line therapy of metastatic disease;
- To describe the laboratory test method, the type of mutation request (if available) and the method and route by which the result was communicated to the physicians (result report);
- To describe and to analyse the time to receipt the KRAS and NRAS results, the process (who ordered the test and when) and the therapeutic approach chosen during this period